

# Cognitive Behavioural Suicide Prevention for psychosis

<b>Submission date</b> 21/05/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 21/05/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 09/09/2016	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Nick Tarrier

**Contact details**  
Zochonis Building  
Brunswick Street  
Oxford Road  
Manchester  
United Kingdom  
M13 9PL  
+44 161 306 6000  
[nicholas.tarrier@manchester.ac.uk](mailto:nicholas.tarrier@manchester.ac.uk)

## Additional identifiers

**Protocol serial number**  
6329

## Study information

**Scientific Title**  
Prevention of Suicide risk in patients with psychosis through the development of a focused and conceptually-driven intervention

**Acronym**

CBSPP

**Study objectives**

Study aims:

1. To confirm and describe the psychological architecture that drives suicide behaviour, this consists of: information processing biases, suicide schema and appraisal systems. We intend to investigate hypotheses relating to determine the role of these in suicide behaviour specifically we will use information processing tasks such as autobiographical memory tasks to investigate bias; standardised assessment to investigate appraisal and schema.
2. To derive a method of assessing this architecture through semi-structured interview that will have clinical utility
3. To formulate and develop a manualised cognitive behavioural treatment programme for suicide prevention in psychosis and to test the clinical acceptance and feasibility of this intervention. It is hypothesised that the treatment will be acceptable, feasible and reduce suicide behaviour.
4. At the end of the programme we will be in position to design a clinical trial to test the efficacy of the intervention

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Stockport REC , 12/12/2008, ref: 08/H1012/97

**Study design**

Multicentre randomised interventional treatment trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Topic: Mental Health Research Network; Subtopic: Psychosis; Disease: Psychosis

**Interventions**

Those allocated to the experimental treatment will receive CBSPP as described in the manual in addition to treatment as usual (TAU). Treatment will take place over 12 weeks. Participants will be seen twice weekly. The control group will receive TAU alone. All participants will be re-assessed at 4 months and at 6 months.

Study entry: single randomisation only

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

Suicidal behaviour, measured at 4 months and 6 months

**Key secondary outcome(s)**

Measured at baseline, 4 months and 6 months:

1. Beck Anxiety Inventory (BAI) to assess level of anxiety
2. Beck Hopelessness Scale
3. Calgary Depression Scale for Schizophrenia
4. Global assessment of functioning (DSM-IV) to assess overall functioning
5. Positive And Negative Symptoms Scale (PANSS) to assess severity of symptoms
6. Psychotic Symptom Rating Scales (PSYRATS) to assess control over symptoms
7. Questionnaire about the Process of Recovery (QPR)
8. Self Esteem Rating Scale
9. The Subjective Experiences of Psychotic Symptoms Scale (SEPSS)

**Completion date**

31/12/2010

**Eligibility****Key inclusion criteria**

1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder or psychotic disorder not otherwise specified (NOS)
2. Have had previous suicide attempts or current suicidal ideation
3. Are not currently acutely suicidal or considered a danger to themselves or others
4. Are receiving appropriate anti-psychotic medication
5. Are under the care of an appropriate clinical team and have contact with mental health service
6. Males and females aged between 18 and 65 years

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

Not providing informed consent

**Date of first enrolment**

01/02/2009

**Date of final enrolment**

31/12/2010

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Zochonis Building**

Manchester

United Kingdom

M13 9PL

## Sponsor information

**Organisation**

University of Manchester (UK)

**ROR**

<https://ror.org/027m9bs27>

## Funder(s)

**Funder type**

Government

**Funder Name**

National Institute for Health Research (NIHR) (UK)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes